Salud financiera de hoja de balance de Arrowhead Pharmaceuticals
Salud financiera controles de criterios 4/6
Arrowhead Pharmaceuticals tiene un patrimonio de los accionistas total de $173.7M y una deuda total de $273.7M, lo que sitúa su ratio deuda-patrimonio en 157.6%. Sus activos y pasivos totales son $626.3M y $452.6M respectivamente.
Información clave
157.6%
Ratio deuda-patrimonio
US$273.69m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$213.38m |
| Patrimonio | US$173.71m |
| Total pasivo | US$452.57m |
| Activos totales | US$626.29m |
Actualizaciones recientes sobre salud financiera
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19
We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18Recent updates
Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Arrowhead Pharma: We Can Afford To Wait For More Proof
Jun 28Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18Arrowhead Pharma: Know Pros' Calcs For Coming Stock Prices
Apr 14Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 46%?
Feb 08Arrowhead: 2021 Was A Struggle Valuation Wise - Things May Get Worse In 2022
Jan 26Accumulate Arrowhead For Its RNAi Pipeline
Jan 17Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($237.9M) de ARWR superan a sus pasivos a corto plazo ($63.7M).
Pasivo a largo plazo: Los activos a corto plazo ($237.9M) de ARWR no cubren sus pasivos a largo plazo ($388.8M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (34.7%) de ARWR se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de ARWR ha crecido de 0% a 157.6% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ARWR tiene suficiente cash runway para 6 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.
Pronóstico de cash runway: Se prevé que ARWR disponga de suficiente cash runway para 5 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.